Inappropriate opening of the mitochondrial permeability transition pore (MPTP) manifests in ischemia[REF] (blood flow restriction to tissue) and reperfusion injury[REF] (damage occurring after ischemia when blood flow returns to tissue), after myocardial infarction[REF] (heart attack) and when mutations in mitochondrial DNA polymerase occur [REF].
CsA has been shown to decrease cardiac hypertrophy by affecting cardiac myocytes in many ways.